These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12996493)

  • 1. Comparative neutralizing antibody patterns to Lansing (type 2) poliomyelitis virus in different populations.
    PAUL JR; MELNICK JL; RIORDAN JT
    Am J Hyg; 1952 Nov; 56(3):232-51. PubMed ID: 12996493
    [No Abstract]   [Full Text] [Related]  

  • 2. Lansing poliomyelitis virus neutralizing antibody titers of different types of human serum.
    LEVINSON SO; MILZER A; WOLF AM
    Ill Med J; 1951 Oct; 100(4):238-40. PubMed ID: 14873311
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistence of neutralizing antibody for a year following vaccination of monkeys with Lansing poliomyelitis virus.
    MORGAN IM
    Proc Soc Exp Biol Med; 1950 Nov; 75(2):305-8. PubMed ID: 14808241
    [No Abstract]   [Full Text] [Related]  

  • 4. Age incidence and seasonal development of neutralizing antibodies to lansing poliomyelitis virus.
    TURNER TB; HOLLANDER DH; BUCKLEY S; KOKKO UP; WINSOR CP
    Am J Hyg; 1950 Nov; 52(3):323-47. PubMed ID: 14789759
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sero-neutralizing antibodies against poliomyelitis virus II (Lansing) in inhabitants of Bucharest].
    CAJAL N; LISSIEVICI-OPRESCU E
    Stud Cercet Inframicrobiol; 1956; 7(1-2):57-63. PubMed ID: 13380643
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement-fixing antibodies to type 2 (Lansing) poliomyelitis virus in a normal population of a subtropical area.
    GOLDBLUM N; MELNICK JL
    J Exp Med; 1952 Aug; 96(2):175-85. PubMed ID: 14955573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antibody in experimental poliomyelitis; reproducibility of endpoint in a mouse neutralization test with Lansing poliomyelitis virus.
    MORGAN IM
    Am J Hyg; 1947 May; 45(3):372-8. PubMed ID: 20240022
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunity to poliomyelitis in Gothenburg in spring of 1954; frequency of persons with neutralizing antibodies to the three types of poliomyelitis virus.
    FAXEN N; HYRENIUS H; WESTMAN A
    Arch Gesamte Virusforsch; 1957; 7(2):206-11. PubMed ID: 13395389
    [No Abstract]   [Full Text] [Related]  

  • 9. Levels of homotypic neutralizing antibody in human poliomyelitis three years after infection.
    WINSSER J; SABIN AB
    J Exp Med; 1952 Nov; 96(5):477-90. PubMed ID: 13000058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.
    SABIN AB
    J Exp Med; 1952 Jul; 96(1):99-106. PubMed ID: 14946332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A specific complement-fixation test for infection with poliomyelitis virus.
    CASALS J; OLITSKY PK; ANSLOW RO
    J Exp Med; 1951 Aug; 94(2):123-37. PubMed ID: 14861374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of serum antibody associated with intracerebral immunity in monkeys vaccinated with Lansing poliomyelitis virus.
    MORGAN IM
    J Immunol; 1949 Jul; 62(3):301-10. PubMed ID: 18132343
    [No Abstract]   [Full Text] [Related]  

  • 13. Dissociation of poliomyelitis virus from neutralizing antibody.
    HUMMELER K; KETLER A
    Virology; 1958 Aug; 6(1):297-9. PubMed ID: 13581538
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparative study of various methods of titration of virus-neutralizing antibodies to poliomyelitis virus in tissue culture].
    GINSBURG NN; KASYMOV KT; AL'TSHTEIN AD
    Vopr Virusol; 1960; 5():20-5. PubMed ID: 13850244
    [No Abstract]   [Full Text] [Related]  

  • 15. Studies on passive immunity in poliomyelitis. III. Production of immune serum to Lansing poliomyelitis virus in rhesus monkeys.
    RHODES AJ; CLARK EM; SHIMADA FT; DONOHUE WL; RITCHIE RC
    Can J Med Sci; 1952 Feb; 30(1):54-67. PubMed ID: 14905334
    [No Abstract]   [Full Text] [Related]  

  • 16. The quantitation of poliomyelitis virus in the human alimentary tract with reference to coexisting levels of homologous serum neutralizing antibody.
    HOWE HA
    Am J Hyg; 1962 Jan; 75():1-17. PubMed ID: 14449394
    [No Abstract]   [Full Text] [Related]  

  • 17. THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY. III. SEQUENTIAL CHANGES IN ELECTROPHORETIC MOBILITY OF 19S AND 7S ANTIBODIES SYNTHESIZED BY RABBITS AFTER A SINGLE VIRUS INJECTION.
    SVEHAG SE
    J Exp Med; 1964 Feb; 119(2):225-40. PubMed ID: 14164480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis.
    MELNICK JL; LEDINKO N
    Am J Hyg; 1953 Sep; 58(2):207-22. PubMed ID: 13080261
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of prolonged storage at 4 to 5 degree C. on the neutralizing antibody of antiserum against poliomyelitis virus.
    OLITSKY PK; MURPHY LC
    J Lab Clin Med; 1950 Jul; 36(1):163-6. PubMed ID: 15428751
    [No Abstract]   [Full Text] [Related]  

  • 20. Formation of neutralizing antibody in monkeys injected with poliomyelitis virus and adjuvants.
    WARD R; RADER D; LIPTON MM; FREUND J
    Proc Soc Exp Biol Med; 1950 Jul; 74(3):536-9. PubMed ID: 15440879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.